All available clinical trials

CARPE DIEM Study: Cognition, Age and Rapamycin Effectiveness-Downregulation of the mTor Pathway

The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

Eligibility: Adults, ages 55 to 85, diagnosed with mild cognitive impairment or early stages of Alzheimer’s disease

COVID-19 Survey

The Biggs Institute for Alzheimer’s and Neurodegenerative Diseases is collaborating with the Multicultural Alzheimer’s Prevention Program (MAPP) at Massachusetts General Hospital to learn more about the general impact of COVID-19 on the well-being, cognition and behavior of Latinos.

Eligibility: Adults, ages 55 and older, self-identified as Latino

Gait Study

The purpose of this clinical trial is to collect data to study how gait patterns in older adults correlate with brain function.

Eligibility: Adults, over 65 years of age, with worsening memory, but no diagnosis of dementia, or have difficulty walking or climbing stairs.

Heart Function and Brain Health Study

The purpose of this clinical trial is to study heart function in relation to brain health.

Eligibility: Adults, ages 60 years or older, doctor referral with normal heart function or diastolic dysfunction and no significant memory concerns

MarkVCID Study: Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia

The purpose of this study is to identify the early indicators that can help us distinguish future healthy aging from dementia.

Eligibility: Adults, aged 55 years or older, self-identified as a Mexican-American and currently living in the San Antonio area

MIND Study: Memory Improvement Through Nicotine Dosing

The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with mild cognitive impairment (MCI).

Eligibility: Healthy, non-smoking adults, age 55+ who notice changes in their memory or whose family member notice changes.

SIESTA Study: Sleep Issues – Efficacy and Sensitivity of Technological Assessments

To provide easier, convenient testing in the future, this study will evaluate if at-home devices, like the FitBit, can detect these sleep disturbances in Parkinson’s with similar accuracy as a clinic-based sleep study.

Eligibility: Diagnosis of Parkinson’s disease and have a study partner that is knowledgeable about participant’s sleep habits

SToMP-AD Study: Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease

The purpose of this study is to evaluate if a combination of two medications may be an effective intervention for treating AD symptoms in future studies.

Eligibility: Adults, aged 65 years or older, with a diagnosis of Alzheimer’s disease